Today: 9 April 2026
Subscribe
Browse Category

Biotechnology 30 December 2025 - 4 January 2026

INBS stock drops today as Intelligent Bio Solutions’ $10M private placement puts dilution in focus

INBS stock drops today as Intelligent Bio Solutions’ $10M private placement puts dilution in focus

Intelligent Bio Solutions shares fell 12.1% to $8.38 in late morning trading after announcing a $10 million private placement with two tranches of warrants. The deal, priced at $4.35 per share and warrant, follows a manufacturing partnership with Syrma Johari MedTech aimed at cutting costs and boosting margins ahead of a planned 2026 U.S. launch.
2 January 2026
··
Cytokinetics (CYTK) stock closes up 3.5% into year-end as Myqorzo launch nears, insider sale disclosed

Cytokinetics (CYTK) stock closes up 3.5% into year-end as Myqorzo launch nears, insider sale disclosed

Cytokinetics shares closed up 3.5% at $63.54, ahead of the planned U.S. launch of Myqorzo for obstructive hypertrophic cardiomyopathy. EVP Andrew Callos sold 1,809 shares at $62.44 under a preset trading plan, retaining 51,353 shares. Investors await U.S. pricing, early prescription data, and a late February earnings update. Myqorzo carries a boxed warning and REMS safety requirements.
2 January 2026
·
CRISPR Therapeutics stock (CRSP) slips into 2026 as New Year’s Day shuts Wall Street — what investors watch next

CRISPR Therapeutics stock (CRSP) slips into 2026 as New Year’s Day shuts Wall Street — what investors watch next

CRISPR Therapeutics shares closed down 1.4% at $52.44 on Dec. 31, the final trading day of 2025. U.S. markets were shut Jan. 1 for New Year’s. Investors are watching for early-2026 updates on Casgevy’s rollout and the next earnings schedule as trading resumes Jan. 2. Biotech ETFs were little changed in light year-end trading.
2 January 2026
······
Axsome Therapeutics (AXSM) stock jumps after FDA sets April 30 decision for Alzheimer’s agitation drug

Axsome Therapeutics (AXSM) stock jumps after FDA sets April 30 decision for Alzheimer’s agitation drug

Axsome Therapeutics shares surged 23% to $182.64 after the FDA accepted its supplemental application for AXS-05 in Alzheimer’s agitation and granted priority review. The stock traded on heavy volume, swinging between $148.79 and $184.40. Axsome also said its AXS-12 narcolepsy drug remains on track for a January 2026 filing. Markets will reopen Friday after the New Year’s Day holiday.
1 January 2026
···
Cytokinetics (CYTK) stock ends 2025 higher as Myqorzo launch nears — what’s next

Cytokinetics (CYTK) stock ends 2025 higher as Myqorzo launch nears — what’s next

Cytokinetics shares closed 2025 up 3.5% at $63.54 after FDA cleared Myqorzo for obstructive hypertrophic cardiomyopathy. The drug, set to launch in January under a REMS program and boxed warning, will compete with Bristol Myers Squibb’s Camzyos. Chief Commercial Officer Andrew Callos sold 1,809 shares at $62.44 each on Dec. 29 under a pre-arranged plan. U.S. markets reopen Friday after the New Year’s holiday.
1 January 2026
····
Axsome stock jumps 23% after FDA sets April 30 deadline for Alzheimer’s agitation review

Axsome stock jumps 23% after FDA sets April 30 deadline for Alzheimer’s agitation review

Axsome Therapeutics shares surged 22.9% to $182.64 after the FDA granted priority review to its application for AXS-05 in treating agitation in Alzheimer’s disease, setting an April 30 decision date. The company also plans to file for approval of AXS-12 for cataplexy in narcolepsy this month, following supportive FDA meeting minutes. Trading volume reached 3.1 million shares.
1 January 2026
··
INBS stock whipsaws after Intelligent Bio Solutions lines up $10 million funding

INBS stock whipsaws after Intelligent Bio Solutions lines up $10 million funding

Intelligent Bio Solutions shares jumped 132% to $9.53 before dropping 14% after-hours as the company announced a $10 million private placement and a new manufacturing deal with Syrma Johari MedTech. The placement, priced at $4.35 per share and warrants, is set well below the closing price. Volume hit 108 million shares. The company recently enacted a 1-for-10 reverse split after a Nasdaq minimum bid warning.
1 January 2026
··
BillionToOne (BLLN) stock slides 4% in thin year-end trade as investors look to January catalysts

BillionToOne (BLLN) stock slides 4% in thin year-end trade as investors look to January catalysts

BillionToOne shares fell 4% to $81.61 in thin trading on the last day of 2025, underperforming diagnostics peers. The company last reported third-quarter revenue of $83.5 million, up 117% year over year, and forecast full-year revenue of $293 million to $299 million. No new company disclosures appeared Wednesday. Management is set to present at the J.P. Morgan Healthcare Conference on Jan. 12.
31 December 2025
··
Cytokinetics stock jumps today as CYTK traders focus on Myqorzo launch and insider filing

Cytokinetics stock jumps today as CYTK traders focus on Myqorzo launch and insider filing

Cytokinetics shares climbed 3.7% to $63.63 Wednesday, bucking a weaker market as investors awaited Myqorzo’s U.S. launch in January. A Form 4 showed Chief Commercial Officer Andrew Callos sold 1,809 shares at $62.44 on Dec. 29 under a pre-set plan. The drug, approved this month, will be distributed with a REMS safety program. Investors are watching for pricing details and initial uptake.
31 December 2025
··
INBS stock surges 160% as Intelligent Bio Solutions strikes manufacturing deal targeting 40% cost cuts

INBS stock surges 160% as Intelligent Bio Solutions strikes manufacturing deal targeting 40% cost cuts

Intelligent Bio Solutions shares jumped 160% to $10.66 after announcing a manufacturing deal with Syrma Johari MedTech to scale production of its fingerprint drug-screening device. The company expects over 40% annual production cost savings and a 20-point gross margin boost. Trading volume hit 48.13 million shares, far above average. The stock traded between $5.62 and $11.52 after closing at $4.10 Tuesday.
31 December 2025
··
GRAIL stock drops in New York session as Galleri FDA filing timeline returns to focus

GRAIL stock drops in New York session as Galleri FDA filing timeline returns to focus

GRAIL shares dropped 3.3% to $84.95 Tuesday afternoon, extending a two-day slide. An Oregon Health & Science University release highlighted PATHFINDER 2 data and confirmed a first-quarter 2026 FDA submission for Galleri. Investors await management’s Jan. 12 update at the J.P. Morgan Healthcare Conference. The stock is down 7.2% since Friday’s close.
30 December 2025
··
Kymera Therapeutics (KYMR) stock falls today as biotech slips — what traders are watching

Kymera Therapeutics (KYMR) stock falls today as biotech slips — what traders are watching

Kymera Therapeutics shares fell 3% to $77.94 Tuesday afternoon, underperforming a 1.4% drop in the SPDR S&P Biotech ETF. The decline follows December’s $692 million equity raise and positive Phase 1b data for its STAT6 degrader KT-621. The stock traded about 9% below its recent $86 offering price. Investors are watching for updates on trial progress and cash burn ahead of 2026 milestones.
30 December 2025
··
1 … 4 5 6 7 8 … 16

Stock Market Today

  • Ares Management (ARES) Share Price Drops 37% YTD, Valuation Concerns Raised
    April 8, 2026, 8:05 PM EDT. Ares Management's (ARES) shares have fallen 37% year-to-date despite solid long-term gains, highlighting shifting investor sentiment in alternative asset managers. The stock trades around $104.83, but valuation models suggest a lower intrinsic value of $87.61, implying a 19.7% overvaluation. Metrics like book value ($12.68 per share) and earnings per share ($5.79) underpin this analysis. Ares' high return on equity (27.6%) contrasts with a cost of equity at $1.93, yet excess returns indicate value creation may not justify the current share price. Investors are advised to weigh fee-based revenue models against market risk reassessments. Simply Wall St rates ARES 0/6 on valuation checks, signaling caution amid volatile market conditions.

Latest article

Why IREN Stock Is Back in Focus as AI Ambitions Meet Funding Fears

Why IREN Stock Is Back in Focus as AI Ambitions Meet Funding Fears

8 April 2026
IREN shares rose 1.8% to $35.74 Wednesday as investors assessed its $6 billion share program and shift from bitcoin mining to AI cloud services. The company’s revenue fell to $184.7 million last quarter, with a net loss of $155.4 million. IREN recently announced a five-year, $9.7 billion AI cloud deal with Microsoft. Options trading volume hit 103,000 contracts Tuesday, with sentiment described as mixed.
Amazon Stock Could Jump 50% as Wall Street Reconsiders Its $200 Billion AI Bet

Amazon Stock Could Jump 50% as Wall Street Reconsiders Its $200 Billion AI Bet

8 April 2026
Amazon closed at $213.77 Tuesday, with BNP Paribas maintaining a $320 price target, citing strong AI demand despite Amazon’s planned $200 billion capex for 2026. The company’s February forecast of higher spending sent shares down 11.5% after hours, even as AWS revenue rose 24% to $35.6 billion in the December quarter. Alphabet and Microsoft are also ramping up AI infrastructure spending.
Sensex Soars 2,946 Points, Nifty Near 24,000 After Iran Ceasefire and RBI Pause

Sensex Soars 2,946 Points, Nifty Near 24,000 After Iran Ceasefire and RBI Pause

8 April 2026
The Sensex surged 2,946 points to 77,562.90 on Wednesday, its best day in five years, as a U.S.-Iran ceasefire and steady RBI rates pushed Indian markets higher. Brent crude fell 14.4% to $93.49 a barrel, easing pressure on the rupee, which rose 0.5% to 92.58 per dollar. All 16 major sectors gained, led by financials and auto stocks. The RBI kept its repo rate at 5.25% and forecast slower growth ahead.
Netflix Stock Draws Fresh Institutional Buying Ahead of Earnings After Goldman Upgrade

Netflix Stock Draws Fresh Institutional Buying Ahead of Earnings After Goldman Upgrade

8 April 2026
Stock Yards Bank & Trust Co. increased its Netflix stake by 1,141.9% to 29,074 shares in Q4, while Ethos Capital Management disclosed a new 19,610-share position worth $1.84 million. The moves come ahead of Netflix’s April 16 earnings report and follow a Goldman Sachs upgrade to Buy with a $120 target. Insiders Reed Hastings and Greg Peters sold shares earlier this year under preset trading plans. Netflix last traded at $98.82.
Alphabet Stock (GOOG, GOOGL) Faces Split Fund Bets Ahead of Earnings After Fresh 13F Reports

Alphabet Stock (GOOG, GOOGL) Faces Split Fund Bets Ahead of Earnings After Fresh 13F Reports

8 April 2026
Zevenbergen Capital increased its Alphabet Class A share holdings by 27.4% in Q4, while Lombard Odier and Empirical Wealth Management reduced their Class C positions, according to April 7 filings. Alphabet will report first-quarter results on April 29. GOOG and GOOGL traded near $304 before Wednesday’s U.S. open. The filings reflect holdings as of December 31 and may not show current positions.
Go toTop